



May 5, 2008

MannKind Corporation Reports First Quarter Financial Results

- Conference Call Today at 5:00 p.m. EDT -

VALENCIA, Calif., May 5 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2008.

For the first quarter of 2008, total operating expenses were \$74.1 million, compared to \$77.3 million for the first quarter of 2007. Research and development (R&D) expenses decreased by \$5.3 million to \$58.4 million for the first quarter of 2008 compared to the first quarter of 2007, primarily due to lower clinical trial costs and associated packaging costs for clinical materials, partially offset by higher stock compensation expense. General and administrative (G&A) expenses increased by \$2.1 million to \$15.6 million for the first quarter of 2008 compared to the first quarter of 2007 primarily due to additional patent expenses.

The net loss applicable to common stockholders for the first quarter of 2008 was \$71.4 million, or \$0.70 per share based on 101.4 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of \$73.1 million, or \$1.00 per share based on 73.4 million weighted average shares outstanding for the first quarter of 2007.

Cash and cash equivalents were \$269.1 million at March 31, 2008 and \$368.3 million at December 31, 2007.

Conference Call

MannKind management will host a conference call to discuss these results today at 5:00 p.m. EDT. To participate in the call, please dial (800) 857-0373 or (210) 839-8507. To listen to the call via the internet, please visit <http://www.mannkindcorp.com>. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (866) 457-6651 or (203) 369-1300.

Presenting from the Company will be:

- Chairman and Chief Executive Officer Alfred Mann
- President and Chief Operating Officer Hakan Edstrom
- Corporate Vice President and Chief Financial Officer Matthew Pfeffer
- Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit <http://www.mannkindcorp.com>.

(Tables to follow)

MannKind Corporation
Condensed Statements of Operations
(Unaudited)
(in thousands, except per share amounts)

| | Three Months Ended March 31, | |
|---|------------------------------|------------|
| | 2008 | 2007 |
| Revenue | \$20 | \$10 |
| Operating expenses: | | |
| Research and development | 58,445 | 63,788 |
| General and administrative | 15,640 | 13,550 |
| Total operating expenses | 74,085 | 77,338 |
| Loss from operations | (74,065) | (77,328) |
| Other income | 60 | 52 |
| Interest expense on senior convertible notes | (337) | (1,145) |
| Interest income | 2,921 | 5,280 |
| Loss before provision for income taxes | (71,421) | (73,141) |
| Income taxes | - | - |
| Net loss applicable to common stockholders | \$(71,421) | \$(73,141) |
| Net loss per share applicable to common stockholders - basic and diluted | \$(0.70) | \$(1.00) |
| Shares used to compute basic and diluted net loss per share applicable to common stockholders | 101,409 | 73,388 |

MannKind Corporation
Condensed Balance Sheets
(Unaudited)
(in thousands)

| | March 31, 2008 | December 31, 2007 |
|--|-------------------|----------------------|
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$269,079 | \$368,285 |
| State research and development tax credit exchange receivable - current | - | 831 |
| Prepaid expenses and other current assets | 8,004 | 9,596 |
| Total current assets | 277,083 | 378,712 |
| Property and equipment - net | 185,895 | 162,683 |
| State research and development tax credit exchange receivable - net of current portion | 1,875 | 1,500 |
| Other assets | 549 | 548 |
| Total | \$465,402 | \$543,443 |
| Liabilities and Stockholders' Equity | | |
| Current liabilities | \$55,447 | \$67,558 |
| Other liabilities | - | 24 |
| Senior convertible notes | 111,882 | 111,761 |
| Stockholders' equity | 298,073 | 364,100 |

Total

\$465,402

\$543,443

SOURCE MannKind Corporation

CONTACT:

Matthew Pfeffer,
Chief Financial Officer
of MannKind Corporation,
+1-661-295-4784,
mpfeffer@mannkindcorp.com

Web site: <http://www.mannkindcorp.com>